Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Alnylam Pharmaceuticals Is Getting Crushed Today

By George Budwell - Oct 6, 2016 at 9:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A major clinical setback sent Alnylam's shares spiraling downward today.

 

Image source: Getty Images.

What happened

Shares of drugmaker Alnylam Pharmaceuticals ( ALNY 3.29% ), which uses RNA interference (RNAi) technology, dropped by more than 44% in pre-market trading today due to a major clinical setback. In short, management decided to nix the development of the company's second most advanced product candidate, revusiran, which was in a late-stage study for hereditary ATTR amyloidosis with cardiomyopathy, a rare condition that typically results in heart failure. According to Alnylam's statement on the matter, an unblinded review "revealed an imbalance of mortality in the revusiran arm as compared to placebo," implying that the drug's benefits may not outweigh its risks. 

So what

Alnylam appeared primed to have two major orphan drugs on the market by 2019, with the experimental treatment for the familial amyloidotic polyneuropathy form of ATTR, patisiran, on track to garner a regulatory approval in 2018. The company's plans obviously took a big hit with this unexpected setback, and perhaps most importantly, it may have wiped out nearly a billion in annual revenue moving forward. 

Now what

The silver lining, if there is one, is that patisiran's clinical program won't be affected by this news. So, with patisiran's ongoing late-stage study expected to product top-line data in the second half of 2017, Alnylam still stands a good shot at transforming into a commercial operation in 2018. And that's not too shabby, given that patisiran is forecast to generate peak sales of $700 million to $800 million. 

That being said, this isn't the first time RNA-interference-based drugs have run into serious safety problems in the clinic, so this latest setback is sure to cast a long shadow over this promising technology. Big pharma, after all, has kept its distance to a large degree from this novel therapeutic platform, choosing to sign licensing deals with Alnylam and others, instead of acquiring RNAi drugmakers outright. As things stand, it might be a good idea to take a wait-and-see approach with this biotech for the time being, perhaps until patisiran's pivotal data readout is closer at hand.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$177.00 (3.29%) $5.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.